No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:20:51.251Z. Latest historical point 2023-02-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T13:20:51.251Z. Latest historical point 2023-02-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T13:20:51.251Z. Latest historical point 2022-02-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T13:20:51.251Z. Latest historical point 2022-02-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T13:20:51.251Z. Latest historical point 2023-02-28.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T13:20:51.251Z. Latest historical point 2023-02-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T13:20:51.251Z. Latest historical point 2022-02-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T13:20:51.251Z. Latest historical point 2022-02-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Atea Pharmaceuticals, Inc. (AVIR) stock was $5.13 as of Oct 5, 2026, 4:00 PM EDT, unchanged from the previous close.
Longer view (total return, dividends reinvested): past 12 months +76.4% · 3-year avg +19.4%/yr · 5-year avg -34.4%/yr
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Biotechnology · Boston, MA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.51
Revenue Est.
$50.45M
Last Quarter Results
EPS
$-0.41
vs Estimate
$-0.56
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1AVIR | $410.54M | $5.13 | +0.00% | +76.42% | -34.44% | N/A | N/A |
| 2EIKN | $408.21M | $7.54 | +2.86% | N/A | N/A | N/A | vs AVIR |
| 3SI | $406.47M | $19.60 | +3.10% | +60.42% | N/A | N/A | vs AVIR |
| 4CARL | $415.93M | $15.30 | +7.22% | +17.87% | N/A | N/A | vs AVIR |
| 5ARCT | $416.68M | $14.66 | +12.51% | -34.88% | -18.73% | -2.54% | vs AVIR |
| 6EDIT | $428.16M | $2.79 | +6.49% | -28.71% | -40.76% | -15.75% | vs AVIR |
forward FY estimate
N/A
$0.00
vs Estimate
$33.03M
Consensus Rating
Based on 3 analysts
Average Price Target
$9.42
+83.6% upside
Low
$7.00
Current
$5.13
High
$11.25
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.58 | $-0.51 | $-0.42 | 2 |
| Quarter ending Dec 2026 | $-0.72 | $-0.57 | $-0.42 | 2 |
| Quarter ending Mar 2027 | $-0.44 | $-0.44 | $-0.44 | 1 |
| Quarter ending Jun 2027 | $-0.45 | $-0.45 | $-0.45 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.20 | $-1.99 | $-1.76 | 1 |
| FY 2027 | $-1.76 | $-1.48 | $-1.20 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $50.45M | $50.45M | $50.45M | 1 |
| Quarter ending Dec 2026 | $6.58M | $6.58M | $6.58M | 1 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $5.74M | $5.74M | $5.74M | 1 |
| FY 2027 | $30.00M | $30.00M | $30.00M | 1 |
